FABP3 levels are increased in the CSF of patients with AD compared to those in normal individuals, and attempts have been made to use it as a biomarker for AD prediction and progression [60]; however, whether FABP functionally affects the development and progression of AD has not been determined conclusively. The gene discussed is FABP3; the disease is Alzheimer disease.